35 related articles for article (PubMed ID: 25282036)
1. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas.
Jamieson A; Vermij L; Kramer CJH; Jobsen JJ; Jürgemlienk-Schulz I; Lutgens L; Mens JW; Haverkort MAD; Slot A; Nout RA; Oosting J; Carlson J; Howitt BE; Ip PPC; Lax SF; McCluggage WG; Singh N; McAlpine JN; Creutzberg CL; Horeweg N; Gilks CB; Bosse T
Clin Cancer Res; 2023 Dec; 29(23):4949-4957. PubMed ID: 37773079
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the localization of chondroitin sulfate in various types of endometrial carcinoma.
Hosokawa S; Norimatsu Y; Shinagawa A; Kurokawa T; Yoshida Y; Nishikawa T; Suzuki H; Irino S; Kobayashi TK
PLoS One; 2024; 19(5):e0304420. PubMed ID: 38805498
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in Low-grade Endometrial Endometrioid Carcinoma.
Lee Y; Choi S; Kim HS
Int J Gynecol Pathol; 2024 May; 43(3):221-232. PubMed ID: 37566876
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary metastasis of stage I, low-grade endometrioid carcinoma: two case reports and the literature review.
Wang L; Li Y; Han L
Front Oncol; 2023; 13():1266485. PubMed ID: 37901321
[TBL] [Abstract][Full Text] [Related]
5.
Kiewisz J; Waśniewski T; Kieżun J; Skowrońska A; Kaczmarek MM; Szóstak B; Kowalczyk AE; Kmieć Z
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835474
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
7. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
Němejcová K; Bártů MK; Michálková R; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Singh N; Stolnicu S; Škapa P; Švajdler M; Stružinská I; Cibula D; Kocian R; Lax SF; McCluggage WG; Dundr P
Diagn Pathol; 2023 Feb; 18(1):15. PubMed ID: 36740684
[TBL] [Abstract][Full Text] [Related]
10. Generation and Integrated Analysis of Advanced Patient-Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer.
Devis-Jauregui L; Vidal A; Plata-Peña L; Santacana M; García-Mulero S; Bonifaci N; Noguera-Delgado E; Ruiz N; Gil M; Dorca E; Llobet FJ; Coll-Iglesias L; Gassner K; Martinez-Iniesta M; Rodriguez-Barrueco R; Barahona M; Marti L; Viñals F; Ponce J; Sanz-Pamplona R; Piulats JM; Vivancos A; Matias-Guiu X; Villanueva A; Llobet-Navas D
Adv Sci (Weinh); 2022 Nov; 10(1):e2204211. PubMed ID: 36373729
[TBL] [Abstract][Full Text] [Related]
11. Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.
Mota A; Oltra SS; Selenica P; Moiola CP; Casas-Arozamena C; López-Gil C; Diaz E; Gatius S; Ruiz-Miro M; Calvo A; Rojo-Sebastián A; Hurtado P; Piñeiro R; Colas E; Gil-Moreno A; Reis-Filho JS; Muinelo-Romay L; Abal M; Matias-Guiu X; Weigelt B; Moreno-Bueno G
Oncogene; 2022 Mar; 41(13):1835-1850. PubMed ID: 35145232
[TBL] [Abstract][Full Text] [Related]
12. The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.
Goebel EA; Vidal A; Matias-Guiu X; Blake Gilks C
Virchows Arch; 2018 Jun; 472(6):885-896. PubMed ID: 29234950
[TBL] [Abstract][Full Text] [Related]
13. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.
Talhouk A; McAlpine JN
Gynecol Oncol Res Pract; 2016; 3():14. PubMed ID: 27999680
[TBL] [Abstract][Full Text] [Related]
14. Practical issues in the diagnosis of serous carcinoma of the endometrium.
Gatius S; Matias-Guiu X
Mod Pathol; 2016 Jan; 29 Suppl 1():S45-58. PubMed ID: 26715173
[TBL] [Abstract][Full Text] [Related]
15. OKN-007 decreases free radical levels in a preclinical F98 rat glioma model.
Coutinho de Souza P; Smith N; Atolagbe O; Ziegler J; Njoku C; Lerner M; Ehrenshaft M; Mason RP; Meek B; Plafker SM; Saunders D; Mamedova N; Towner RA
Free Radic Biol Med; 2015 Oct; 87():157-68. PubMed ID: 26119786
[TBL] [Abstract][Full Text] [Related]
16. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry.
Santacana M; Maiques O; Valls J; Gatius S; Abó AI; López-García MÁ; Mota A; Reventós J; Moreno-Bueno G; Palacios J; Bartosch C; Dolcet X; Matias-Guiu X
Hum Pathol; 2014 Dec; 45(12):2394-403. PubMed ID: 25282036
[TBL] [Abstract][Full Text] [Related]
17. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
18. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
19. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
Alkushi A; Köbel M; Kalloger SE; Gilks CB
Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
